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Introduction
Most patients with chronic daily headache have a history of ep-
isodic migraine that has gradually evolved into the chronic form. 
This gradual transformation during the most productive years 
of adulthood leads to profound disability, which is costly to the 
public health system.
1,2 The process of migraine transformation 
is complex and involves multiple risk factors, but the main con-
tributor is not known.
3,4 Previous studies have found that genet-
ic factors and familial clustering affect the development of chron-
ic tension-type headache; however, few studies have analyzed 
in detail the role of genetic factors in the transformation of mi-
graine into chronic daily headache.
5-7
The progression of migraine is postulated to result from chang-
es in nociceptive thresholds and the ensuing central sensitiza-
tion caused by recurrent migraine in susceptible individuals.
8 
It is well known that glutamate is released from the trigeminal 
ganglion along with calcitonin gene-related peptide, activating 
the central nervous system structure involved in migraine patho-
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Background and PurposezzThe progression of migraine into chronic daily headache involves 
multiple risk factors, but the main contributor is not known. Glutamate is the major excitatory neu-
rotransmitter in central sensitization, which is an important process in the pathogenesis of migraine 
transformation. The glutamate transporter protein excitatory amino acid transporter 2 (EAAT2) is 
the primary modulator of glutamatergic neurotransmission, and genetic polymorphisms of its gene, 
EEAT2, have been identified. The aim of this study was to determine the effect of EAAT2 polymor-
phisms on migraine transformation into chronic daily headache.
MethodszzWe included 74 migraine patients with episodic attack (M-E) and 59 migraine pa-
tients with chronic daily headache (M-CDH). After amplifying EAAT2 by polymerase chain reac-
tion, we assessed its genotype frequencies based on restriction fragment length polymorphisms. We 
reclassified all migraine patients into two groups according to their EAAT2 genotype, either with the 
A allele (n=62) or without it (n=71), and compared the clinical variables between the two groups.
ResultszzThe genotype frequencies of EAAT2 polymorphisms did not differ between the M-E 
and M-CDH groups. Comparison between EEAT2 genotypes revealed that the frequency of anal-
gesic usage was significantly higher among migraine patients with the A allele (12.9±1.6 days/
month) than in those without the A allele (8.1±1.2 days/month; p=0.019). The other clinical vari-
ables of migraine did not differ between the two groups.
ConclusionszzThe results suggest that EEAT2 polymorphism contributes to the tendency to-
ward frequent analgesic usage in migraine patients. This implies a potential genetic influence on 
the progression of migraine into chronic daily headache through the development of medication-
overuse headache.
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physiology.
9,10 Central sensitization following peripheral senso-
ry stimulation is mediated by glutamate receptor activation.
11 
There is evidence from animal studies that increased glutamate 
levels parallel enlargement in the sensory thresholds of facial 
receptive fields,
12 thus further supporting the involvement of glu-
tamate in the development of cutaneous allodynia, as observed 
in migraineurs. Glutamate levels in the cerebrospinal fluid are 
significantly elevated in patients with chronic migraine as com-
pared to those in control subjects.
13,14
Excitatory amino acid transporters (EAATs) play a key role in 
the regulation of glutamate levels in the central nervous system.
15 
EAATs transport glutamate into astrocytes for conversion into glu-
tamine, which is then released and recycled by neurons to gener-
ate glutamate.
16 Thus far, five human EAATs have been cloned,
15,17 
among which excitatory amino acid transporter 2 (EAAT2) is re-
sponsible for up to 90% of all glutamate transport.
18 The human 
EAAT2 gene is located on 11q13-13, and polymorphisms in the 
EAAT2 promoter affect the putative regulatory site for activator 
protein-2 and create different transcriptional efficiencies.
19,20 
Therefore, differences in genotype could be associated with dif-
ferential glutamate neurotransmission. The potential roles of the 
functional polymorphisms of the glutamate transporter protein 
in various neurological disorders, such as multiple sclerosis, amy-
otrophic lateral sclerosis, and epilepsy, have been the subject of 
several studies.
21-23 A mutation of EAAT1 reportedly causes a de-
cline in glutamate uptake in patients with hemiplegic migraine and 
episodic ataxia.
24 However, no studies have examined the associ-
ation between EAAT2 polymorphisms and migraine.
The aim of the present study was to elucidate the contribution 
of glutamate transporter protein polymorphism in the transfor-
mation of migraine into chronic daily headache.
Methods
Subjects
All of the subjects included in this study were identified from a 
larger pool of subjects taking part in an ongoing prospective 
study of the genetic basis of headache at the Headache Clinic 
of the Catholic University of Korea. We recruited 133 consecu-
tive patients with migraine from the Headache Clinic. None of 
the participants were from the same family. Given the known ef-
fects of gender on the gene system, only women were includ-
ed in this study. The subjects were patients diagnosed with mi-
graine or chronic migraine who had not taken preventive me-
dications for headache. This study was approved by the institu-
tional ethical committee of our institute, and written informed 
consent to participate was obtained from all included subjects.
All of the participants were clinically assessed and examined 
physically and neurologically by an experienced neurologist. 
During the interview, detailed data were obtained regarding their 
clinical symptoms, headache variables and analgesics that were 
taken for abortive treatment for their headaches using a diary 
composed of structured questionnaires. We classified migraine 
patients who suffer from headaches for less than 15 days/month 
as having episodic migraine (M-E; n=74), and those who suf-
fer from headaches for 15 days/month or more as having mi-
graine with chronic daily headache (M-CDH; n=59). The M-
CDH group included patients with chronic migraine, probable 
chronic migraine with medication overuse, and migraine com-
bined with other types of headache. Migraine was diagnosed 
according to the International Classification of Headache Dis-
orders, 2nd edition.
25
Determination of the EAAT2 genotype
Blood samples were collected into heparinized tubes and stored 
at -80℃ before isolation of DNA. Genomic DNA was isolat-
ed and amplified by polymerase chain reaction (PCR) using 
the specific oligonucleotide primers 5’-GAG CGG CGG GGC 
CTC TTT TC-3’ and 5’-TGC AGC CGC TGC CAC CTG TG-
3’. PCR reaction mixtures contained 50 ng of genomic DNA, 
20 pmol of each primer, 10 mM Tris-HCl, 50 mM KCl, 1.5 mM 
MgCl2, each of dATP, dCTP, dGTP, and dTTP at 200 μM, and 
1.25 units of Taq polymerase in a total volume of 50 μL (Pro-
mega, Wisconsin, USA). The following cycling conditions 
were used: 1) an initial denaturation at 95℃ for 5 min; 2) 35 
cycles of denaturation at 95℃ for 1 min, annealing at 57℃ for 
1 min, and extension at 72℃ for 1 min; and 3) a final extension 
at 72℃ for 3 min. PCR was conducted in a thermal cycler (Bio-
Rad, California, USA). The resulting PCR products were sub-
jected to restriction digestion overnight at 37℃ using 5 units of 
BcnI (Takara Bio, Shiga, Japan). The digested products were sep-
arated at 100 V for 40 min on a 2% agarose gel (Bio-Rad) con-
taining 10 mg/mL ethidium bromide. The gel was visualized un-
der ultraviolet light using a gel electrophoresis visualization 
system (Spectroline, New York, USA). The A allele gave 381-
bp fragments and the C allele gave 262- and 119-bp fragments. 
Genotyping was based on the independent scoring of the results 
by two reviewers who were blinded to the case/control status.
Associations of migraine phenotypes with 
EAAT2 genotypes
We classified all migraine patients according to their EAAT2 
genotype: individuals with the A allele (n=62; A/A and A/C gen-
otypes) or individuals without the A allele (n=71; C/C genotype). 
The following clinical variables of headache were compared be-
tween the two groups: pain index of headache intensity, as mea-
sured on a visual analog scale; headache frequency (days/month); 
duration of each headache attack (hours per attack); and frequen-
cy of analgesic use for headache (days/month) during the pre-
vious 6 months.Shin HE et al.
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Data analysis
Comparisons of genotype distribution between the M-E and M-
CDH groups were performed on raw frequencies using the χ
2 
test. A χ
2 analysis of the Hardy-Weinberg equilibrium for the 
genotypes was conducted to determine whether the allele fre-
quencies were stable. For the comparisons of clinical variables 
of migraine headache according to EAAT2 polymorphism, we 
used a t-test for parametric continuous variables. SPSS statisti-
cal software (version 10.0; SSPS, IL, USA) was used in all anal-
yses, and the level of statistical significance was set at p＜0.05.
Results
The genotype distributions in patients with migraine did not 
deviate from that expected based on Hardy-Weinberg equilib-
rium. The genotype frequencies for the EAAT2 promoter poly-
morphism did not differ significantly between the M-E and M-
CDH groups (Table 1). The frequency of analgesics usage was 
higher among migraine patients with the A allele (Table 2): 
12.9 and 8.1 days/month in migraine patients with and without 
the A allele, respectively (p=0.019). The clinical variables of 
migraine including headache frequency, duration of headache 
attack, and headache intensity did not differ significantly be-
tween the two groups (Table 2).
Discussion
Recent advances have shed light on the pathogenic mechanisms 
of migraine transformation, and glutamate-mediated excitato-
ry pathways are one of the putative candidates in the develop-
ment and maintenance of chronic headache through the action 
of glutamate on ionotropic and metabotropic receptors.
26,27 The 
transformation of episodic migraine into chronic daily headache 
changes characteristics such as the frequency and intensity of 
the headaches.
The present study was initially designed to evaluate the role 
of polymorphism of EAAT2, a genetic component related to 
glutamate metabolism, in the transformation of migraine into 
chronic daily headache. However, the genotype distribution of 
EAAT2 polymorphisms did not differ between M-E and M-
CDH. Moreover, we found no difference in the frequency of head-
ache attack, which is one of the most important requisites for 
the diagnosis of chronic migraine. The pain intensity and duration 
of migraine attack also did not differ between the two EAAT2 
genotypes. On the basis of these results, we could not confirm 
whether the genetic factor associated with EAAT2 polymorphism 
plays a contributory role in the transformation of migraine into 
chronic daily headache through the enhancement of pain gen-
eration or a perception mechanism. The glutamatergic system 
is regulated in a complicated manner, and so it is possible that 
factors other than EAAT2 polymorphism play a role in this pro-
cess of transformation. Further studies are needed to investi-
gate the potential function of these factors in migraine trans-
formation.
The present study identified differences in the pattern of an-
algesic usage for migraine attack according to EAAT2 poly-
morphism. It is well known that frequent use of analgesics re-
sults in medication overuse in primary headache, which has 
been regarded as a causative factor for the transformation into 
chronic daily headache.
28,29 In the pathophysiology of medica-
tion-overuse and transformed migraines, there is considerable 
overlap in the mechanisms mediating migraine headache pain 
and analgesic-induced paradoxical pain. The chronic adminis-
tration of morphine has been found to increase the expression 
of calcitonin gene-related peptide and central changes in prima-
ry afferent neurons, enhance descending facilitation, and increase 
excitatory neurotransmission.
30,31 Results from studies using spe-
cialized magnetic resonance imaging techniques showed high 
iron levels due to analgesic overuse in the midbrain periaque-
ductal gray of patients with chronic daily headache. The degree 
of iron load was correlated with the duration of analgesic use. 
Dysfunction in the periaqueductal gray due to frequent analge-
Table 1. Genotype distribution of EEAT2 in patients with M-E or 
M-CDH
Subject 
group
Genotype distribution
N
Individuals
with the A allele 
N (%)
Individuals
without the A allele
N (%)
M-E 74 29 (40%) 45 (60%)
M-CDH 59 33 (56%) 26 (44%)
Genotype distribution: χ2=3.698, df=1, p=0.08. 
EEAT2: excitatory amino acid transporter 2.
Table 2. Comparison of migraine characteristics between patients with the A allele and those without it
Individuals with the A allele Individuals without the A allele p
Age (years) 44.5±1.7 41.8±1.4 NS
Duration of illness (years) 10.5±0.8 08.8±1.0 NS
Frequency of headache attack (days/month) 12.8±1.4 12.2±1.2 NS
Duration of headache attack (hours/attack) 23.4±2.6 27.7±2.7 NS
Pain index (visual analog scale) 08.0±0.2 07.8±0.2 NS
Frequency of analgesic usage (days/month) 12.9±1.6 08.1±1.2 0.019
Data are mean±SEM valuesEAAT2 Polymorphism in Chronic Migraine 
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sic use results in medication-overuse headache in migraine pa-
tients, as this region is the center of a descending antinocicep-
tive neuronal network.
32
While medication overuse and chronic migraine are linked, 
the actual causal path-that is whether analgesics overuse is a 
cause or consequence of pain progression-is still a matter of de-
bate. In the present study, EAAT2 polymorphism influenced 
the pattern of analgesic usage without affecting the headache 
characteristics, which suggests an independent role of anal-
gesics overuse in migraine transformation.
Analgesics overuse has long been considered a “biobehavior-
al” disorder, in which the biological predisposition to develop a 
chronic daily headache interacts with the behavior of an indi-
vidual who is prone to develop a dependence disorder.
33,34 A ge-
netic association study found that about one-third of patients with 
analgesic-overuse headache had a family history of drug or sub-
stance abuse.
6 Likewise, Ferrari et al.
35 found that drug abuse 
was significantly higher among the first-degree relatives of 
chronic migraine patients than among those of episodic migraine 
patients. A genetic predisposition to drug abuse has been traced 
to polymorphisms in neurotransmitter, which is implicated in 
migraine pathogenesis.
6,7 Although no study has shown a direct 
relationship between analgesic overuse and EAAT2 polymor-
phism, a few genetic association studies have found that it might 
be associated with predisposition to alcohol dependence and 
the personality trait related to compulsive substance-seeking 
behavior.
36
Inadequately treated headache or pain remains a major chal-
lenge in pain therapy, and it can lead patients to further analge-
sic use. It has been reported that the variable success rates of 
pharmacologic therapy may be related to the different poly-
morphisms of various genetic dispositions in patients who re-
spond to analgesics.
37,38 Genetic variants may alter the pharma-
codynamic mechanisms controlling the interaction between the 
analgesic molecules and their target structures.
39 In chronic mi-
graine, analysis of the association between genetic polymorphism 
and grade of response to triptan administration showed a signifi-
cant correlation.
40,41 These results could be part of an integrat-
ed platform for evaluating genetic influences in drug metabo-
lism and medication overuse in chronic migraine patients.
In summary, the results of the present study have revealed that 
EAAT2 polymorphism (a genetic component related to gluta-
mate metabolism) influences analgesic overuse in patients with 
migraine. Although our results do not indicate a direct associa-
tion between this genetic factor and chronic migraine, we sug-
gest a genetic influence on migraine transformation throughout 
the development of medication-overuse headache. Familial ag-
gregation studies and large genetic epidemiological surveys are 
needed to confirm these results.
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